Why the workflow is different
Sublocade is not picked up from a standard retail pharmacy. The medication is coordinated through certified handling pathways and administered by a provider in clinic.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Ask for the costs of evaluation, medication, monitoring and follow-up separately. Coverage is specific to your plan and the actual service. Confirm the provider, product and benefits before assuming that a quoted amount includes the whole plan.
Sublocade is not dispensed to patients at a regular retail pharmacy for take-home use. Certified healthcare settings and pharmacies supply it directly to a healthcare provider for administration through the Sublocade REMS program. Confirm which provider will receive and give your injection, and whether delivery is complete before traveling. Manufacturer assistance has separate eligibility rules and covers neither every visit charge nor every patient.
Ask who submits any required authorization, what information is missing and how you will receive an update. Confirm the likely out-of-pocket amount with the responsible provider, insurer and pharmacy. If access is delayed, ask the clinician for a safe continuity or alternative plan rather than changing treatment yourself.
Sublocade is a long-acting buprenorphine injection for moderate to severe opioid use disorder. A clinician gives it under the skin; you do not take it home or inject it yourself. It can replace the daily task of taking a buprenorphine film or tablet for some patients. The decision also depends on withdrawal risk, your response to buprenorphine, health history and whether you can return for ongoing care.
The evaluation first confirms opioid use disorder and reviews recent fentanyl, heroin, pain-pill, methadone and buprenorphine use. Some patients already taking transmucosal buprenorphine can transition directly. Patients who are new to buprenorphine need a supervised first dose and assessment of tolerability. Pregnancy, liver disease, breathing problems and sedating medicines require an individualized discussion; moderate or severe liver impairment can make this depot unsuitable.
Bring the name and strength of your current product, the last dose, your usual schedule and any gaps. Describe cravings, withdrawal, sedation, substance use and previous overdoses. These details help the clinician distinguish an access problem from a treatment plan that needs to change.
The current label allows starting after a single supervised transmucosal dose when the patient tolerates it. It does not require every patient to spend seven days on daily medication first. The clinician assesses withdrawal before initiation, observes response to the first medicine and monitors symptoms after the injection before deciding that it is safe to leave.
Ask whether the evaluation and injection are separate appointments, which site will administer the medicine and who confirms delivery. Clinical approval, insurance authorization and medication arrival are separate steps. Keep a clinician-directed medication plan in place while those steps are completed.
Follow-up covers cravings, opioid use, constipation or other side effects, injection-site healing and recovery goals. Discuss counseling and practical support that would help you. Agree on a contact route for symptoms between visits and a plan for missed appointments, travel and changes in insurance.
Bring medication containers or a current list, allergies, past treatment records and recent laboratory results if available. Tell the clinician about alcohol, benzodiazepines, sleep medicines and other sedatives. Discuss planned surgery or dental treatment before the injection. Ask how long the first visit may take and whether you need help getting home if you feel sleepy. Do not change your daily medication or timing from an online conversion chart.
Sublocade carries a boxed warning because injection into a vein can cause serious harm or death. Only a healthcare provider administers it through the restricted REMS pathway. Alcohol and other sedatives can increase breathing and overdose risks. Do not drive or operate machinery until you know how treatment affects you. Do not rub, cut or try to remove the injection depot. Seek prompt assessment for worsening pain, swelling, drainage or skin breakdown. Call 911 for slow breathing, inability to wake, a seizure or another medical emergency; use available overdose-reversal medicine for a suspected opioid overdose.
Maintenance injections are generally monthly, but the first two visits can follow a different schedule. Tell the team early if cravings or withdrawal return. A missed injection needs a clinician plan, not a borrowed film or an extra opioid. If treatment stops, buprenorphine can remain in the body for a long time, so withdrawal and medication interactions may need monitoring for months. Discuss any wish to taper without assuming that an injection guarantees a painless end to treatment.
Ask for separate estimates for evaluation, medication, administration, testing and follow-up. Confirm the authorization period and the plan if approval or shipment is delayed. Manufacturer support has its own eligibility rules and does not establish your total clinic cost. Confirm the actual administration site before arranging time away from work; confirm that the medicine and injection visit are arranged.
Sublocade is a long-acting buprenorphine injection for moderate to severe opioid use disorder. A clinician gives it under the skin; you do not take it home or inject it yourself. It can replace the daily task of taking a buprenorphine film or tablet for some patients. The decision also depends on withdrawal risk, your response to buprenorphine, health history and whether you can return for ongoing care.
Bring the name and strength of your current product, the last dose, your usual schedule and any gaps. Describe cravings, withdrawal, sedation, substance use and previous overdoses. These details help the clinician distinguish an access problem from a treatment plan that needs to change.
The current label allows starting after a single supervised transmucosal dose when the patient tolerates it. It does not require every patient to spend seven days on daily medication first. The clinician assesses withdrawal before initiation, observes response to the first medicine and monitors symptoms after the injection before deciding that it is safe to leave.
Ask whether the evaluation and injection are separate appointments, which site will administer the medicine and who confirms delivery. Clinical approval, insurance authorization and medication arrival are separate steps. Keep a clinician-directed medication plan in place while those steps are completed.
Follow-up covers cravings, opioid use, constipation or other side effects, injection-site healing and recovery goals. Discuss counseling and practical support that would help you. Agree on a contact route for symptoms between visits and a plan for missed appointments, travel and changes in insurance.
Maintenance injections are generally monthly, but the first two visits can follow a different schedule. Tell the team early if cravings or withdrawal return. A missed injection needs a clinician plan, not a borrowed film or an extra opioid. If treatment stops, buprenorphine can remain in the body for a long time, so withdrawal and medication interactions may need monitoring for months. Discuss any wish to taper without assuming that an injection guarantees a painless end to treatment.
Ask for separate estimates for evaluation, medication, administration, testing and follow-up. Confirm the authorization period and the plan if approval or shipment is delayed. Manufacturer support has its own eligibility rules and does not establish your total clinic cost. Confirm the actual administration site before arranging time away from work; confirm that the medicine and injection visit are arranged.
Bring the name and strength of your current product, the last dose, your usual schedule and any gaps. Describe cravings, withdrawal, sedation, substance use and previous overdoses. These details help the clinician distinguish an access problem from a treatment plan that needs to change.
The current label allows starting after a single supervised transmucosal dose when the patient tolerates it. It does not require every patient to spend seven days on daily medication first. The clinician assesses withdrawal before initiation, observes response to the first medicine and monitors symptoms after the injection before deciding that it is safe to leave.
Ask whether the evaluation and injection are separate appointments, which site will administer the medicine and who confirms delivery. Clinical approval, insurance authorization and medication arrival are separate steps. Keep a clinician-directed medication plan in place while those steps are completed.
Follow-up covers cravings, opioid use, constipation or other side effects, injection-site healing and recovery goals. Discuss counseling and practical support that would help you. Agree on a contact route for symptoms between visits and a plan for missed appointments, travel and changes in insurance.
Sublocade carries a boxed warning because injection into a vein can cause serious harm or death. Only a healthcare provider administers it through the restricted REMS pathway. Alcohol and other sedatives can increase breathing and overdose risks. Do not drive or operate machinery until you know how treatment affects you. Do not rub, cut or try to remove the injection depot. Seek prompt assessment for worsening pain, swelling, drainage or skin breakdown. Call 911 for slow breathing, inability to wake, a seizure or another medical emergency; use available overdose-reversal medicine for a suspected opioid overdose.
Ask for separate estimates for evaluation, medication, administration, testing and follow-up. Confirm the authorization period and the plan if approval or shipment is delayed. Manufacturer support has its own eligibility rules and does not establish your total clinic cost. Confirm the actual administration site before arranging time away from work; confirm that the medicine and injection visit are arranged.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
Stopping needs an individualized plan. Long-acting buprenorphine can delay withdrawal, and some patients need months of follow-up after the last injection. Forum reports of an easy taper cannot predict your experience. Review cravings, relapse risk and ongoing support before deciding to stop.
No. Coverage approval, medication acquisition and a confirmed administration visit are separate tasks. Ask which step is complete and what remains, and request the total expected costs rather than relying on a medicine-only estimate.
The manufacturer lists $2,202.03 per month for both strengths, based on information accurate January 1, 2026 and checked October 9, 2026. This is a manufacturer list-price reference, not a Nao Medical quote or your final bill. Without coverage, ask for a written estimate that separates the medicine, evaluation, injection administration, testing and follow-up. Your actual charge can differ from list price. Manufacturer copay assistance requires eligible private coverage and is not available to uninsured patients.
Medicaid coverage and patient charges depend on the state program, plan, treatment setting and authorization requirements. Ask the plan to check Sublocade and the intended administering provider. Confirm whether the medicine, injection administration and visits are covered separately. The manufacturer’s private-insurance copay program excludes Medicaid. Published claims averages do not establish your current benefit or mean every Medicaid patient pays nothing.
Many plans cover Sublocade, but your benefits must be checked for the product, provider and treatment setting. Ask which medical or pharmacy benefit applies, whether prior authorization is needed, and what you owe for the medicine and other services. Eligible privately insured adults may qualify for manufacturer copay assistance, subject to terms and limits. It covers the medicine only and excludes government insurance. Approval does not confirm that medication has arrived or an injection has been given.
Sublocade is not picked up from a standard retail pharmacy. The medication is coordinated through certified handling pathways and administered by a provider in clinic.
The medication and the visit can have different insurance steps. That is why benefits review, prior authorization, and coverage questions often need to be clarified before treatment moves forward.
The injection appointment needs to line up with medication availability. Good coordination prevents wasted visits and last-minute confusion.
Patients should expect the team to confirm insurance details, office scheduling, and medication logistics before treating the first injection like a done deal.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx option for monthly Sublocade follow-up, transition review, and practical medication coordination close to home.
View local Sublocade care Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A western Queens location for monthly buprenorphine injection visits, benefits review, and structured addiction medicine follow-up.
View local Sublocade care Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx site for Sublocade scheduling, pharmacy coordination, and repeat injection care.
View local Sublocade care Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A central Brooklyn location for monthly injection care with realistic neighborhood access for follow-up.
View local Sublocade care Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island option for Sublocade treatment, specialty-pharmacy coordination, and ongoing recovery visits.
View local Sublocade care Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens clinic for transition review, monthly injection planning, and repeat follow-up.
View local Sublocade care Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A southeast Queens location for monthly Sublocade visits, benefits review, and addiction medicine support.
View local Sublocade care Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A workday-friendly Queens site for monthly buprenorphine injection follow-up and practical care coordination.
View local Sublocade care Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A core Long Island location for monthly injection treatment, scheduling, and pharmacy coordination.
View local Sublocade care Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan option for structured monthly Sublocade follow-up and reliable in-city access.
View local Sublocade care Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn location for monthly injection care, transition planning, and repeat follow-up visits.
View local Sublocade care Get directionsThe first question is not just whether someone wants the injection. It is whether recent opioid use, current buprenorphine treatment, and medication tolerance support a safe transition.
The first phase covers evaluation, transition review when needed, benefits confirmation, and medication coordination so the plan is lined up before a treatment slot is used.
The Sublocade family currently covers Brooklyn, Queens, the Bronx, Manhattan, and Long Island so the treatment plan does not depend on one hard-to-reach clinic.
Broader MAT visits across the network cover same-day access, bridge planning, fentanyl dependence, and local treatment options.
Daily buprenorphine treatment remains an important option for many patients before or alongside any discussion of longer-acting injectable care.
A separate injectable pathway is available when the question is monthly naltrexone rather than monthly buprenorphine.
Medication comparison separates Suboxone, Sublocade, Vivitrol, and naloxone safety planning so patients can understand which question each one answers.
Buprenorphine guidance explains how daily treatment and longer-acting injection care fit into the broader medication plan.
Telemedicine can support evaluation and follow-up when clinically appropriate, with local locations available when in-person care is needed.
When the immediate issue is how fast someone can be evaluated and started safely, the same-day pathway matters more than the injection discussion.
Short-gap medication questions are handled through the bridge pathway rather than improvised refill assumptions.
Recent fentanyl exposure can change how buprenorphine-based treatment is approached and timed.
Arrange an evaluation to discuss suitable care, preparation and follow-up with a clinician.
See active Sublocade locationsNao Medical provides outpatient addiction care. The first visit can focus on the immediate clinical question and medication planning when relevant. When wanted or clinically recommended, the care plan can also include counseling, recovery support, and closer follow-up. Related information: outpatient addiction care.
Patients who want more support can add counseling, relapse-prevention work, care coordination, and recovery follow-up through the outpatient addiction program.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking. Review addiction-treatment insurance support
Content was updated August 2, 2026 from the cited sources and Nao Medical's current service information. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.